Inogen, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2017

The activity for stock options under the Company’s stock plans is as follows:

								Remaining
								weighted-
						Weighted-		average		Per share
						average		contractual		average
				Price per		exercise		terms		intrinsic
	Options			share		price		(in years)		value
Outstanding as of December 31, 2016		2,355,527		$0.60-$58.95		$	28.22		5.42	$	38.95
Granted		64,498			83.30		83.30
Exercised		(308,132	)	0.60-56.72			21.68
Forfeited		(62,424	)	24.52-58.95			43.75
Expired		(33	)		8.70		8.70
Outstanding as of June 30, 2017		2,049,436		0.60-83.30			30.47		5.07		64.95
Vested and exercisable as of June 30, 2017		1,106,535		0.60-83.30			21.62		4.83		73.80
Vested and expected to vest as of June 30, 2017		1,984,249		$0.60-$83.30		$	30.18		5.06	$	65.24

Summary of Restricted Stock Units Activity

RSU activity for the six months ended June 30, 2017, is summarized below:

			Weighted-
			average grant
			date fair value
	Units		per share
Unvested as of December 31, 2016		—	$	—
Granted		5,700		73.26
Vested		—		—
Forfeited/canceled		—		—
Unvested as of June 30, 2017		5,700	$	73.26

Summary of Stock-based Compensation Expense

Stock-based compensation

Stock-based compensation expense recognized for the three months and six months ended June 30, 2017 and June 30, 2016 was as follows:

	Three months ended				Six months ended
	June 30,				June 30,
	2017		2016		2017		2016
Stock-based compensation expense by type of award:
Stock option plan awards	$	2,055	$	2,001	$	3,799	$	3,205
Restricted stock units		24		—		48		—
Employee stock purchase plan		137		155		260		246
Total stock-based compensation expense	$	2,216	$	2,156	$	4,107	$	3,451

For the three months and six months ended June 30, 2017 and June 30, 2016, stock-based compensation expense recognized under ASC 718, included in cost of revenues, sales and marketing expense, general and administrative expense, and research and development expense was as follows:

	Three months ended				Six months ended
	June 30,				June 30,
	2017		2016		2017		2016
Cost of revenue	$	212	$	160	$	403	$	279
Research and development		250		207		473		338
Sales and marketing		347		314		662		541
General and administrative		1,407		1,475		2,569		2,293
Total stock-based compensation expense	$	2,216	$	2,156	$	4,107	$	3,451